IDEXX Laboratories Croissance future
Future contrôle des critères 2/6
IDEXX Laboratories devrait augmenter ses bénéfices et son chiffre d'affaires de 9.6% et de 8.1% par an respectivement. Le BPA devrait croître de de 11.1% par an. Le rendement des capitaux propres devrait être 38.4% dans 3 ans.
Informations clés
9.6%
Taux de croissance des bénéfices
11.14%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 16.5% |
| Taux de croissance des recettes | 8.1% |
| Rendement futur des capitaux propres | 38.41% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 28 Jul 2026 |
Mises à jour récentes de la croissance future
Recent updates
Seeking Alpha • Jul 07
IDEXX Laboratories Does Not Need More Vet Visits--But It Needs More Tests Per Visit
Summary IDEXX Laboratories (IDXX) is rated Hold, as its premium valuation (~38x 2026E EPS) already assumes strong recurring revenue and diagnostics growth. IDXX is growing diagnostics revenue despite declining veterinary visits, leveraging inVue Dx and Cancer Dx to expand test volumes and market share. inVue Dx and Cancer Dx offer credible market expansion opportunities, but recurring consumables adoption and reference-lab volume growth remain unproven at scale. Scenario analysis shows modest base case upside and meaningful downside risk if consumables adoption or margin expansion underperform expectations. Read the full article on Seeking Alpha
Mise à jour du récit • Jul 01
IDXX: Expanded Diagnostics And Reset Expectations Will Support Future Shareholder Value
Analysts have trimmed their price targets on IDEXX Laboratories by roughly $40. This reflects slightly lower fair value estimates, a modestly reduced revenue growth outlook, and a lower assumed future P/E multiple.
Mise à jour du récit • Jun 17
IDXX: Cooler Street Views Will Meet Raised Outlook And Execution Risks
Analysts have trimmed their price targets on IDEXX Laboratories stock, with the updated fair value estimate now aligned around $530. This reflects a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a marginally lower future P/E multiple.Article d’analyse • Jun 17
IDEXX Laboratories (IDXX) Stock Could Be 23.6% Undervalued as Growth Narrative Faces P/E Test
IDEXX Laboratories (IDXX) stock has attracted fresh attention after recent price moves, with a last close of $573 and mixed short term returns that include a gain over the past month but a decline year to date. See our latest analysis for IDEXX Laboratories. Against a backdrop of mixed trading, IDEXX Laboratories has seen its share price recover in the past month, with a 30 day share price return of 8.36% contrasting with a year to date decline of 14.48%. The 1 year total shareholder return...
Mise à jour du récit • Jun 03
IDXX: Recurring Diagnostics And AI Cancer Testing Will Support Future Earnings Power
Analysts have trimmed IDEXX Laboratories' fair value estimate by $18 to $805. This reflects updated views on growth, profitability and P/E assumptions following a series of recent price target resets and a neutral initiation on the stock.Mise à jour du récit • May 18
IDXX: Cooler Street Views Will Meet Cancer Diagnostics And Margin Execution Focus
For IDEXX Laboratories, the analyst price target has shifted modestly lower to about $530 from roughly $537 as analysts factor in adjusted assumptions for growth, profitability and future P/E multiples following a series of recent target cuts and a new neutral initiation. Analyst Commentary Recent Street research on IDEXX Laboratories points to a more cautious tone, with several price target cuts and a neutral initiation helping pull the average target lower.Mise à jour du récit • May 01
IDXX: Cancer Diagnostics Execution And Margin Discipline Will Guide Cooler Yet Fair Outlook
The updated analyst price target for IDEXX Laboratories has been reduced by about $19, reflecting slightly higher discount assumptions, modestly different margin expectations, and a lower future P/E multiple cited across recent research from several firms. Analyst Commentary Recent Street research for IDEXX Laboratories has leaned cautious, with several bearish analysts lowering their price targets by ranges of about $25 to $100.Mise à jour du récit • Apr 16
IDXX: Recurring Diagnostics And Cancer Testing Will Support Future Earnings Power
Analysts have trimmed their average price target on IDEXX Laboratories by $100. This reflects a more cautious stance, even as updated assumptions for discount rate, revenue growth, profit margins and future P/E remain broadly aligned with prior expectations.Mise à jour du récit • Apr 01
IDXX: Cancer Diagnostics Execution And Margin Resilience Will Shape Fairly Valued Outlook
For IDEXX Laboratories, the updated analyst price target has shifted from about $579 to roughly $556 as analysts adjust their models for slightly different revenue growth and P/E assumptions, while also acknowledging a modestly higher profit margin outlook. Analyst Commentary Recent research updates show a series of lower price targets for IDEXX Laboratories, with bearish analysts trimming their expectations by amounts ranging from about $20 to roughly $100.Mise à jour du récit • Mar 18
IDXX: Recurring Diagnostics And Cancer Testing Will Support Long Term Earnings Power
Narrative Update The analyst price target for IDEXX Laboratories has been reduced by a series of cuts totaling $125, with analysts pointing to updated assumptions for revenue growth, profit margins, and future P/E as key drivers of the change. Analyst Commentary Recent Street research on IDEXX Laboratories has centered on revised price targets, with several firms updating their models to reflect new assumptions for revenue growth, profitability, and P/E.Mise à jour du récit • Mar 04
IDXX: Recurring Diagnostics And Cancer Testing Pipeline Will Support Future Earnings Power
Analysts have trimmed their price target on IDEXX Laboratories by $27 to $823, citing updated assumptions around discount rates, long term growth, and future P/E expectations. Analyst Commentary Recent research commentary on IDEXX Laboratories has centered on recalibrated price targets that incorporate updated assumptions for discount rates, long term growth, and future P/E expectations.Mise à jour du récit • Feb 18
IDXX: New Diagnostics Pipeline And Margin Outlook Will Support Future Shareholder Value
The analyst price target for IDEXX Laboratories has been trimmed by about $4.60 as analysts factor in slightly more measured revenue growth assumptions, a modestly lower future P/E multiple, and a somewhat higher expected profit margin. Analyst Commentary Recent Street research has clustered around lower price targets for IDEXX Laboratories, with cuts of about US$20 to US$50 in quick succession.Mise à jour du récit • Feb 04
IDXX: Recurring Diagnostics And Cancer Testing Pipeline Will Support Long Term Earnings Power
Analysts have reduced their price targets on IDEXX Laboratories by $20 to $30, reflecting updated assumptions around revenue growth, profit margins, and future P/E multiples, while maintaining a broadly similar view of fair value. Analyst Commentary Bullish analysts appear to see the recent price target cuts as more of a recalibration than a shift in their overall thesis on IDEXX Laboratories.Mise à jour du récit • Jan 20
IDXX: Rich P/E Leaves Little Room For Cancer Diagnostics Execution Missteps
Analysts have raised their fair value estimate for IDEXX Laboratories from about US$497 to about US$579, citing higher modeled revenue growth, slightly stronger profit margins, a richer future P/E, and increased confidence in the company's product pipeline and recurring diagnostics growth following recent Q3 results and guidance updates. Analyst Commentary Street research after the Q3 update centers on two themes: confidence in IDEXX Laboratories' recurring diagnostics growth and product pipeline, and questions about how much of that strength is already reflected in the share price.Mise à jour du récit • Jan 06
IDXX: Recurring Diagnostics And Cancer Testing Pipeline Will Support Premium Earnings Power
Analysts have lifted their price targets on IDEXX Laboratories into a US$750 to US$805 range, citing a strong Q3 print, increased 2025 guidance, and what they describe as a compelling diagnostics pipeline along with solid recurring revenue trends as key supports for higher valuations. Analyst Commentary Recent research updates around IDEXX Laboratories cluster around a similar theme, with bullish analysts pointing to a strong Q3, raised 2025 guidance, and a diagnostics portfolio they see as well positioned in current markets.Mise à jour du récit • Dec 16
IDXX Recurring Diagnostics Strength Will Support Premium Earnings Power Ahead
Our updated fair value estimate for IDEXX Laboratories has increased to $850 from $785, as analysts highlight a stronger than expected Q3 performance, accelerating recurring diagnostic revenue growth, and a robust innovation pipeline that supports slightly higher long term growth and margin assumptions despite a modestly higher discount rate. Analyst Commentary Recent Street research reflects a broadly constructive stance on IDEXX Laboratories following its stronger than expected Q3 results and raised 2025 guidance.Mise à jour du récit • Dec 02
IDXX: Recent Performance and Pipeline Progress Will Support Long-Term Shareholder Value
The average analyst price target for IDEXX Laboratories has been raised, reflecting a series of upward revisions. Several targets now surpass $750, as analysts cite stronger-than-expected Q3 results and a constructive outlook on growth, innovation, and recurring revenues.Mise à jour du récit • Nov 18
IDXX: Future Revenue Acceleration Will Drive Premium Multiples and Shareholder Returns
The analyst price target for IDEXX Laboratories has increased significantly, rising by over $50 to approximately $755. Analysts cite a stronger growth outlook, durable pricing, and robust quarterly results as supporting factors for higher valuations.Mise à jour du récit • Nov 03
IDXX: Expanding Installed Base Will Drive Accelerating Business Momentum Ahead
The consensus analyst price target for IDEXX Laboratories has increased by over $22. This reflects growing optimism fueled by expectations of accelerating recurring revenue growth, stronger visit trends, and expanding product adoption in the company's core business lines.Mise à jour du récit • Oct 20
Advanced Diagnostics And International Expansion Will Define Future Opportunity
The analyst fair value estimate for IDEXX Laboratories was adjusted downward to $679.92 from $695.09. Analysts highlighted accelerated consumables growth and an expanding installed base, which support long-term growth potential as market conditions normalize.Article d’analyse • Aug 16
Earnings Not Telling The Story For IDEXX Laboratories, Inc. (NASDAQ:IDXX) After Shares Rise 25%
NasdaqGS:IDXX 1 Year Share Price vs Fair Value Explore IDEXX Laboratories's Fair Values from the Community and select...Article d’analyse • Aug 07
IDEXX Laboratories, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
NasdaqGS:IDXX 1 Year Share Price vs Fair Value Explore IDEXX Laboratories's Fair Values from the Community and select...Mise à jour du récit • Aug 06
Advanced Diagnostics And International Expansion Will Define Future Opportunity
IDEXX Laboratories’ consensus price target has been sharply raised, reflecting strengthened revenue growth forecasts and a higher future P/E multiple, with fair value increasing from $542.55 to $657.55. What's in the News IDEXX Laboratories raised 2025 earnings guidance, increasing revenue outlook to $4,205–$4,280 million (up $90 million at midpoint) and EPS to $12.40–$12.76 (up $0.40 at midpoint), reflecting strong recurring diagnostics revenue, higher inVue Dx instrument placements, and favorable foreign exchange.Seeking Alpha • Apr 14
IDEXX Laboratories: I Love The Business, Not The Stock Price
Summary IDEXX Laboratories is a business that is supported by strong tailwinds, has a sticky business model with predictable, recurring revenue, all supported by an innovation-led growth strategy. There are some concerns like the way management is allocating capital, the tariff risks involving China, lower ROIC, and a declining growth rate. My main concern is with the valuation, as it is hard to justify an earnings multiple in excess of 30 when the growth rate is in the low-teens. Read the full article on Seeking AlphaSeeking Alpha • Mar 12
IDEXX Laboratories: A Top Dog In The Pet Care Market
Summary The pet care industry is growing, with increasing pet ownership and spending, especially in emerging markets, providing IDEXX with significant growth opportunities. IDEXX Laboratories is the market leader with a highly profitable business model, operating leverage, and recurring revenues. Once a customer starts using an IDEXX instrument, it is tied to the IDEXX ecosystem. In the short term, revenue growth will be driven by the recent launch of the IDEXX inVue Dx instrument, the development of the oncology market, and the cloud-based software. Given IDEXX's competitive advantages, market growth potential, and current fair valuation, I initiate coverage with a buy rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 10
IDEXX Laboratories And Its Real Value
Summary IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years. This article focuses on the fundamentals, the real value versus the current share price, and if IDEXX Laboratories is currently worth investing in. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
IDEXX Laboratories Q3: Weak End-Market Demand Continues
Summary I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth. IDEXX's future growth prospects remain promising, but current stock prices do not fully account for weak end-market demands, justifying the 'Sell' rating. Read the full article on Seeking Alpha
Nouveau récit • Aug 19
Global Expansion And Innovative Products Propel Revenue And Margin Growth Amidst Challenges
IDEXX's international and innovative product growth, like the inVue Dx Cellular Analyzer, fuels potential revenue and market share increases globally.Seeking Alpha • Aug 12
IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Summary IDEXX reported lower full-year organic revenue growth due to reduced U.S. clinical visits. Weak consumer sentiment and ongoing staffing challenges may continue to impact clinical visits in the near future. Launch of new menu expansion for Catalyst platform may drive growth in diagnostic business, but the stock remains overvalued. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 5,581 | 1,461 | 1,456 | 1,657 | 11 |
| 12/31/2027 | 5,115 | 1,302 | 1,291 | 1,473 | 14 |
| 12/31/2026 | 4,708 | 1,169 | 1,158 | 1,407 | 14 |
| 3/31/2026 | 4,446 | 1,095 | 1,068 | 1,210 | N/A |
| 12/31/2025 | 4,304 | 1,059 | 1,044 | 1,182 | N/A |
| 9/30/2025 | 4,167 | 1,027 | 940 | 1,088 | N/A |
| 6/30/2025 | 4,038 | 986 | 774 | 906 | N/A |
| 3/31/2025 | 3,932 | 895 | 838 | 968 | N/A |
| 12/31/2024 | 3,898 | 888 | 798 | 929 | N/A |
| 9/30/2024 | 3,845 | 866 | 793 | 917 | N/A |
| 6/30/2024 | 3,785 | 846 | 839 | 969 | N/A |
| 3/31/2024 | 3,725 | 867 | 797 | 921 | N/A |
| 12/31/2023 | 3,661 | 845 | 773 | 907 | N/A |
| 9/30/2023 | 3,588 | 823 | 680 | 830 | N/A |
| 6/30/2023 | 3,514 | 791 | 593 | 747 | N/A |
| 3/31/2023 | 3,431 | 699 | 456 | 612 | N/A |
| 12/31/2022 | 3,367 | 679 | 384 | 543 | N/A |
| 9/30/2022 | 3,340 | 670 | 438 | 580 | N/A |
| 6/30/2022 | 3,309 | 664 | 429 | 578 | N/A |
| 3/31/2022 | 3,274 | 735 | 605 | 746 | N/A |
| 12/31/2021 | 3,215 | 745 | 636 | 756 | N/A |
| 9/30/2021 | 3,135 | 757 | 663 | 765 | N/A |
| 6/30/2021 | 3,047 | 728 | 694 | 770 | N/A |
| 3/31/2021 | 2,858 | 674 | 666 | 745 | N/A |
| 12/31/2020 | 2,707 | 582 | 540 | 648 | N/A |
| 9/30/2020 | 2,591 | 497 | 445 | 585 | N/A |
| 6/30/2020 | 2,475 | 460 | 366 | 524 | N/A |
| 3/31/2020 | 2,457 | 437 | 286 | 453 | N/A |
| 12/31/2019 | 2,407 | 428 | N/A | 459 | N/A |
| 9/30/2019 | 2,351 | 423 | N/A | 439 | N/A |
| 6/30/2019 | 2,291 | 407 | N/A | 418 | N/A |
| 3/31/2019 | 2,252 | 390 | N/A | 400 | N/A |
| 12/31/2018 | 2,213 | 377 | N/A | 400 | N/A |
| 9/30/2018 | 2,170 | 330 | N/A | 386 | N/A |
| 6/30/2018 | 2,117 | 307 | N/A | 386 | N/A |
| 3/31/2018 | 2,045 | 284 | N/A | 377 | N/A |
| 12/31/2017 | 1,969 | 263 | N/A | 373 | N/A |
| 9/30/2017 | 1,906 | 277 | N/A | 353 | N/A |
| 6/30/2017 | 1,862 | 263 | N/A | 343 | N/A |
| 3/31/2017 | 1,820 | 245 | N/A | 343 | N/A |
| 12/31/2016 | 1,775 | 222 | N/A | 339 | N/A |
| 9/30/2016 | 1,732 | 214 | N/A | 312 | N/A |
| 6/30/2016 | 1,690 | 202 | N/A | 289 | N/A |
| 3/31/2016 | 1,637 | 192 | N/A | 258 | N/A |
| 12/31/2015 | 1,602 | 192 | N/A | 222 | N/A |
| 9/30/2015 | 1,554 | 174 | N/A | 170 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de IDXX ( 9.6% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de IDXX ( 9.6% par an) devraient croître plus lentement que le marché US ( 16.7% par an).
Croissance élevée des bénéfices: Les bénéfices de IDXX devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de IDXX ( 8.1% par an) devrait croître plus lentement que le marché de US ( 12.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de IDXX ( 8.1% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de IDXX devrait être élevé dans 3 ans ( 38.4 %)
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/31 21:31 |
| Cours de l'action en fin de journée | 2026/07/31 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
IDEXX Laboratories, Inc. est couverte par 25 analystes. 14 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Navann Ty Dietschi | BNP Paribas |
| Michael Ryskin | BofA Global Research |